Renalytix (STU:2O9) Debt-to-EBITDA : N/A (As of Dec. 2025)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:2O9 Renalytix PLC STU:2O9
12 GF Score
Price €0.07
GF Value €0.04
! 3 Warning Signs
View Full Analysis

What is Renalytix Debt-to-EBITDA?

Debt-to-EBITDA measures a company's ability to pay off its debt.

Renalytix's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was €0.17 Mil. Renalytix's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Dec. 2025 was €4.00 Mil. Renalytix's annualized EBITDA for the quarter that ended in Dec. 2025 was €-25.38 Mil. Renalytix's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2025 was -0.16.

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt. According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

The historical rank and industry rank for Renalytix's Debt-to-EBITDA or its related term are showing as below:

STU:2O9' s Debt-to-EBITDA Range Over the Past 10 Years
Min: -0.39   Med: -0.22   Max: -0.01
Current: -0.28

During the past 7 years, the highest Debt-to-EBITDA Ratio of Renalytix was -0.01. The lowest was -0.39. And the median was -0.22.

STU:2O9's Debt-to-EBITDA is ranked worse than
100% of 482 companies
in the Healthcare Providers & Services industry
Industry Median: 2.2 vs STU:2O9: -0.28

Renalytix  (STU:2O9) Debt-to-EBITDA Explanation

In the calculation of Debt-to-EBITDA, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by EBITDA. In some calculations, Total Liabilities is used to for calculation.

Be Aware

A high Debt-to-EBITDA ratio generally means that a company may spend more time to paying off its debt.

According to Joel Tillinghast's BIG MONEY THINKS SMALL: Biases, Blind Spots, and Smarter Investing, a ratio of Debt-to-EBITDA exceeding four is usually considered scary unless tangible assets cover the debt.

Renalytix Debt-to-EBITDA Related Terms

Renalytix Debt-to-EBITDA Historical Data

* Premium members only.

The historical data trend for Renalytix's Debt-to-EBITDA can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Renalytix Debt-to-EBITDA Chart

Renalytix Annual Data
Trend Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24
Debt-to-EBITDA
Get a 7-Day Free Trial -0.03 0.00 -0.30 -0.26 -0.20

Renalytix Quarterly Data
Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Dec25
Debt-to-EBITDA Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -0.26 -0.20 -0.26 -0.37 N/A

STU:2O9 vs VEEV, BTSG, TEM: Debt-to-EBITDA Comparison

For the Health Information Services subindustry, Renalytix's Debt-to-EBITDA, along with its competitors' market caps and Debt-to-EBITDA data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Renalytix Debt-to-EBITDA vs Healthcare Providers & Services Industry

For the Healthcare Providers & Services industry and Healthcare sector, Renalytix's Debt-to-EBITDA distribution charts can be found below:

* The bar in red indicates where Renalytix's Debt-to-EBITDA falls into.


STU:2O9
12GF Score
Renalytix PLC STU:2O9
Debt-to-EBITDA is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Renalytix Debt-to-EBITDA Calculation

Debt-to-EBITDA measures a company's ability to pay off its debt.

Renalytix's Debt-to-EBITDA for the fiscal year that ended in Jun. 2024 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(3.9188243527333 + 4.0121296944651) / -39.025280431685
=-0.20

Renalytix's annualized Debt-to-EBITDA for the quarter that ended in Dec. 2025 is calculated as

Debt-to-EBITDA=Total Debt / EBITDA
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / EBITDA
=(0.17029247733012 + 4.0018732172579) / -25.380426350678
=-0.16

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Debt-to-EBITDA, the EBITDA of the last fiscal year is used. In calculating the annualized quarterly data, the EBITDA data used here is four times the quarterly (Dec. 2025) EBITDA data.

Is Renalytix (STU:2O9) Overvalued in 2026?

Based on GuruFocus' analysis, Renalytix stock appears to be overvalued. The current stock price of €0.07 is trading 62.5% above its estimated GF Value™ of €0.04.

Key valuation signals for STU:2O9:

  • Debt-to-EBITDA: N/A
  • GF Value™: €0.04 vs. price of €0.07 (62.5% above fair value)
  • GF Score™: 12/100 with 3 warning signs

No single metric tells the full story. See the STU:2O9 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Renalytix Business Description

Other Exchanges RENXF:USARENX:UK2O9:Germany
Address 2 Leman Street, London, GBR, E1W 9US
Renalytix PLC is a developer of artificial intelligence-enabled clinical in vitro diagnostic solutions for kidney disease. Its product, KidneyIntelX, is designed to improve kidney disease diagnosis and prognosis, transplant management, clinical care, patient stratification for drug clinical trials, and drug target discovery. The company's service, KidneyIntelX.dkd, enables the assessment of risk for early-stage chronic kidney disease progression. KidneyIntelX uses a proprietary algorithm combining blood-based biomarkers, inherited genetics, and electronic health record data to generate a patient risk score predicting rapid kidney function decline.
12GF Score

Get the complete analysis for STU:2O9

Debt-to-EBITDA is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.07
Price
€0.04
GF Value